Inria Sophia Antipolis Méditerranée is leading SimCardioTest, a new EU project funded with 8 million Euros that will provide insight into designing new predictive tools in cardiac pathologies. Among the ten partners, the rising startup InSilicoTrials. The search for new drugs and devices is particularly difficult in the case of cardiovascular disease, which remains the leading cause of death worldwide, with 18 million deaths each year according to World Health Organization estimates. Currently, 15 million people in Europe live with heart failure, and it is one of the few cardiovascular diseases whose prevalence continues to rise. Beyond the risk of
The post Inria and InSilicoTrials partner up on a European project leveraging simulation for cardiac devices and drugs appeared first on Pharma Mirror Magazine.
